Semaglutide Dosing for Weight Loss: Personalized Approach

Last reviewed: May 14, 2026

Last updated: May 14, 2026

Written by: Jay Hastings, CEO of PlexusDx

Jay Hastings is the CEO of PlexusDx, a precision health company focused on genetic testing, blood biomarker insights, and personalized wellness recommendations. He has more than 20 years of experience across healthcare innovation, genomics, laboratory operations, healthcare investing, and strategic finance.

Medically reviewed by: Jayden Lee, PharmD, EMBA

Jayden Lee, PharmD, EMBA, is the PlexusDx Medical Science Liaison with a PharmD and MBA specializing in pharmacogenomics and clinical product development, with a proven ability to bridge the gap between genomic research and practical patient outcomes. Dr. Lee has more than 10 years of professional experience in clinical pharmacy, academia, and research.

Semaglutide dosing for weight loss begins at 0.25 mg injected subcutaneously once weekly, with gradual increases every 4 weeks until reaching a maintenance dose, typically 2.4 mg weekly. Clinical trials show this tiered approach reduces gastrointestinal side effects while allowing the body to adjust.

Understanding your individual factors—including genetics, metabolic markers, and medical history—can help inform whether standard dosing protocols will work optimally for you. PlexusDx supports precision-wellness conversations by identifying genetic predispositions in GLP-1 and metabolic pathways relevant to peptide-based treatments.

The Standard Semaglutide Dosing Protocol and Timeline

The FDA-approved semaglutide dosing schedule for weight loss (Wegovy) follows a 16-week escalation: 0.25 mg week 1–4, 0.5 mg week 5–8, 1 mg week 9–12, and 1.7 mg week 13–16, with a final target of 2.4 mg week 17 onward. This gradual increase minimizes nausea and allows GLP-1 receptor adaptation.

Maintenance at 2.4 mg weekly is the dose studied in the STEP trials, where patients achieved average weight loss of 14–22% over 68 weeks. Some patients experience adequate response at lower doses (1.7 mg), while others benefit from the full 2.4 mg dose. Provider guidance is essential for determining your target.

Semaglutide Dosing Comparison: Clinical Evidence and Individual Factors

Clinical and genetic factors influence how your body responds to semaglutide dosing. Age, BMI, baseline metabolism, and GLP-1 receptor variants all contribute to individual variation. The table below outlines key factors your provider may consider when personalizing your dosing approach.

Factor	Clinical Relevance to Dosing
Starting Dose (0.25 mg)	Universal start; minimizes nausea and allows receptor priming over 4 weeks
Escalation Tolerance	Some patients need slower increases; medical history and GI sensitivity guide pace
Target Maintenance (2.4 mg)	Dose used in STEP trials; 40% of patients saw ≥20% weight loss; not all require this dose
GLP1R Genetic Variants	rs6923761 variants may influence receptor sensitivity and individual response trajectory

Why Some Patients Respond Differently to the Same Semaglutide Dose

Genetic variation in the GLP-1 receptor gene, combined with differences in hepatic metabolism and gastric emptying rate, contributes to heterogeneous responses. Two patients on the same 2.4 mg dose may experience different appetite suppression, weight loss rates, and side effect profiles based on underlying biology.

Biomarkers including fasting glucose, insulin resistance, and GLP-1 baseline levels provide additional context for your provider's dosing decisions. While these markers do not predict exact outcomes, they help contextualize whether you may benefit from earlier or later dose escalation.

Safety Considerations and Provider-Guided Dosing Adjustments

Semaglutide carries risks of gastrointestinal side effects, pancreatitis, and gallbladder complications. Patients with personal or family history of medullary thyroid carcinoma, thyroid disease, or diabetic retinopathy should not use semaglutide. Your provider must evaluate contraindications before initiating any dose.

If you experience severe nausea, vomiting, or abdominal pain during escalation, inform your provider immediately. Dose adjustment, extended plateau periods, or discontinuation may be necessary. Compounded semaglutide from licensed 503A pharmacies offers cost flexibility, but medical oversight remains non-negotiable regardless of source.

How PlexusDx Supports a More Personalized Approach

PlexusDx's Precision Peptide Genetic Test examines GLP1R rs6923761 and other variants in peptide metabolism pathways that may help provide context for how your body processes GLP-1 agonists. Certain alleles correlate with differential GLP-1 signaling efficiency, though genetic status does not determine exact dosing or response.

The test also evaluates FTO rs9939609 and MC4R rs17782313 variants related to appetite regulation and metabolic risk. Understanding your genetic predispositions can support a more personalized conversation with your provider about whether standard escalation or a modified dosing approach may be more suitable for your biology.

Combined with clinical assessment, genetic insights may help inform whether you are a candidate for lower-dose maintenance (1.7 mg) or whether full escalation to 2.4 mg is medically appropriate. These results should always be interpreted with your qualified healthcare provider in the context of your complete medical history.

How Your Genetics Influence GLP-1 Response

Not everyone responds to GLP-1 medications the same way. Genetic variants — including GIPR rs1800437, GLP1R rs6923761, FTO rs9939609, and MC4R rs17782313 — influence how your body processes these medications, how much weight you lose, and how you tolerate side effects. PlexusDx maps 14 pathways, 49 peptides, and 150+ genetic insights to match each patient to the right medication, dose, and lifestyle protocol for their biology. The PlexusDx Precision Peptide Genetic Test ($99 add-on after your first month, or $298 standalone) gives your provider precise insight into your peptide genetic predispositions before the first prescription is written.

Access Personalized GLP-1 Care Through PlexusDx

PlexusDx offers six prescription GLP-1 protocols to all 50 states — no membership, no insurance required, async intake or live consult. The Semaglutide Injection starts at $149/mo. Medications are dispensed from licensed 503A compounding pharmacies following strict quality and safety standards. Add a Precision Peptide Genetic Test for $99 to personalize your protocol from day one.

Frequently Asked Questions

What is the starting dose of semaglutide for weight loss, and why is it so low?

Semaglutide begins at 0.25 mg weekly to allow your body to adapt to GLP-1 receptor activation and minimize nausea. This low starting dose is maintained for 4 weeks before escalation, ensuring tolerability and safety.

How long does it take to reach the full 2.4 mg maintenance dose?

The standard escalation timeline is 16–20 weeks: 0.25 mg (weeks 1–4), 0.5 mg (weeks 5–8), 1 mg (weeks 9–12), 1.7 mg (weeks 13–16), and 2.4 mg (week 17 onward). Your provider may adjust this timeline based on tolerability.

Do I have to reach 2.4 mg, or can I stay at a lower dose?

Some patients achieve meaningful weight loss at 1.7 mg or lower doses. Your provider determines your target dose based on efficacy, side effects, and individual response. Lower doses may be appropriate if you see good results with fewer side effects.

What happens if I experience severe nausea during dose escalation?

Contact your provider immediately. Dose escalation can be paused, extended, or reversed if nausea is intolerable. Adjusting meal timing and size often helps. Discontinuation is an option if side effects outweigh benefits.

How might genetic variants in the GLP-1 receptor affect my semaglutide dosing?

Variants like GLP1R rs6923761 may influence how efficiently your receptors respond to semaglutide, potentially affecting dosing strategy. PlexusDx's Precision Peptide Genetic Test identifies these variants to support discussion with your provider about personalized dosing.

Can compounded semaglutide from PlexusDx use a different dosing protocol than Wegovy?

Compounded semaglutide uses the same evidence-based dosing protocols as brand Wegovy. PlexusDx sources from licensed 503A pharmacies and recommends following standard escalation under provider supervision, regardless of formulation.

Understanding the Doses for Semaglutide for Weight Loss